13.98
21-2月-25 16:45:00
15 分の遅延
株式
-0.33
-2.31%
本日の幅
13.57 - 14.80
ISIN
N/A
ソース
NASDAQ
Replimune Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
05 1 2021 08:00:02 提供 Nasdaq GlobeNewswire